Affiliation:
1. St. Luka's Clinical Hospital; Saint-Petersburg State University; S.M. Kirov Military Medical Academy, Ministry of Defense of Russia
2. St. Luka's Clinical Hospital; I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia
3. St. Luka's Clinical Hospital
Abstract
Prostate cancer (PCa) is in second place in oncological morbidity in males and is the fifth leading cause of death among the world's population. According to current world statistics, over the past 20 years there has been an increase in primary morbidity, as well as mortality from PCa. The key to diagnosing PCa is a prostate biopsy. Nevertheless, a systemic biopsy under transrectal ultrasound control is the subject of discussion and debate in oncourology, as it has significant drawbacks that affect the qualitative result of the diagnosis of PCa. Given the importance of adequate and staged PCa, various methods of targeted biopsy under magnetic resonance control have been proposed.This review will examine the main features and significance of targeted prostate biopsy, as well as the role of magnetic resonance imaging in the early diagnosis of PCa. The method of targeted biopsy of the prostate gland can improve the detection of PCa in relation to clinically significant forms. In addition, this method is extremely promising and requires further study to further improve the quality of early diagnosis of PCa, especially when selecting patients for radical surgical treatment.
Publisher
Publishing House ABV Press
Subject
Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference34 articles.
1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol 2019;10(2):63-89. DOI: 10.14740/wjon1191.
2. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424. DOI: 10.3322/caac.21492.
3. Ferlay J., Colombet M., Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144(8):1941—53. DOI: 10.1002/ijc.31937.
4. Berger A.P., Gozzi C., Steiner H. et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol 2004;171(4):1478-80. DOI: 10.1097/01.ju.0000116449.01186.f7.
5. Petrova G.V., Kaprin A.D., Gretsova O.P. et al. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 511 р. (In Russ.).